LIMITED-SAMPLING MODELS FOR ANTICANCER AGENTS

被引：49

作者：

VANWARMERDAM, LJC

HUININK, WWT

MAES, RAA

BEIJNEN, JH

机构：

[1] ANTONI VAN LEEUWENHOEK HOSP,NETHERLANDS CANC INST,DEPT MED ONCOL,1066 CX AMSTERDAM,NETHERLANDS

[2] UNIV UTRECHT,FAC PHARM,DEPT PHARMACEUT ANAL & TOXICOL,3508 TB UTRECHT,NETHERLANDS

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 1994年 / 120卷 / 07期

关键词：

CHEMOTHERAPEUTIC AGENTS; LIMITED-SAMPLING MODELS; PHARMACODYNAMICS; PHARMACOKINETICS;

D O I：

10.1007/BF01240143

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pharmacokinetic parameters of antineoplastic drugs are usually generated from concentration/time profiles obtained after multiple venipunctures. With limited-sampling models (LSM) this number can be reduced to between one and three timed plasma samples. LSMs may facilitate population pharmacokinetic/pharmacodynamic studies, which eventually may lead to a dosing strategy based on the characteristics of the individual patient. In this article, the development, validation and application of several LSMs reported in the literature are reviewed.

引用

收藏

页码：427 / 433

页数：7

相关论文

共 57 条

[21] PHARMACOKINETICS AND PHARMACODYNAMICS OF LOCOREGIONAL 5-FLUOROURACIL (5FU) IN ADVANCED COLORECTAL LIVER METASTASES [J].

GOLDBERG, JA ;

KERR, DJ ;

WILLMOTT, N ;

MCKILLOP, JH ;

MCARDLE, CS .

BRITISH JOURNAL OF CANCER, 1988, 57 (02) :186-189

[22] CLINICAL PHARMACOKINETICS OF CYCLOPHOSPHAMIDE [J].

GROCHOW, LB ;

COLVIN, M .

CLINICAL PHARMACOKINETICS, 1979, 4 (05) :380-394

[23] ACCURACY OF USING PRE-DOSE AND POST-DOSE GENTAMICIN SERUM CONCENTRATIONS TO ESTIMATE PHARMACOKINETIC PARAMETERS AND ADJUST DOSES IN CHILDREN AND ADOLESCENTS [J].

HAMILTON, SF ;

EVANS, WE .

THERAPEUTIC DRUG MONITORING, 1981, 3 (01) :57-61

[24] MULTIPLE-DOSE PHARMACOKINETICS OF EPIRUBICIN AT 4 DIFFERENT DOSE LEVELS - STUDIES IN PATIENTS WITH METASTATIC BREAST-CANCER [J].

JAKOBSEN, P ;

STEINESS, E ;

BASTHOLT, L ;

DALMARK, M ;

LORENZEN, A ;

PETERSEN, D ;

GJEDDE, SB ;

SANDBERG, E ;

ROSE, C ;

NIELSEN, OS ;

MOURIDSEN, HT ;

JAKOBSEN, A .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (01) :63-68

[25] INDIVIDUALIZING DRUG-DOSAGE REGIMENS - ROLES OF POPULATION PHARMACOKINETIC AND DYNAMIC-MODELS, BAYESIAN FITTING, AND ADAPTIVE-CONTROL [J].

JELLIFFE, RW ;

SCHUMITZKY, A ;

VANGUILDER, M ;

LIU, M ;

HU, L ;

MAIRE, P ;

GOMIS, P ;

BARBAUT, X ;

TAHANI, B .

THERAPEUTIC DRUG MONITORING, 1993, 15 (05) :380-393

[26] RELATIONSHIPS BETWEEN CARBOPLATIN EXPOSURE AND TUMOR RESPONSE AND TOXICITY IN PATIENTS WITH OVARIAN-CANCER [J].

JODRELL, DI ;

EGORIN, MJ ;

CANETTA, RM ;

LANGENBERG, P ;

GOLDBLOOM, EP ;

BURROUGHS, JN ;

GOODLOW, JL ;

TAN, S ;

WILTSHAW, E .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :520-528

[27]

JOEL SP, 1990, P AM ASS CLIN ONCOL, V9, P67

[28] HYPOTHESIS FOR THE INDIVIDUALIZATION OF DRUG-DOSAGE [J].

KOUP, JR ;

SACK, CM ;

SMITH, AL ;

GIBALDI, M .

CLINICAL PHARMACOKINETICS, 1979, 4 (06) :460-469

[29]

LAROCCA RV, 1990, NEUROLOGY, V40, P954

[30] A LIMITED SAMPLING PROCEDURE FOR ESTIMATING ADRIAMYCIN PHARMACOKINETICS IN CANCER-PATIENTS [J].

LAUNAY, MC ;

MILANO, G ;

ILIADIS, A ;

FRENAY, M ;

NAMER, N .

BRITISH JOURNAL OF CANCER, 1989, 60 (01) :89-92

← 1 2 3 4 5 6 →